Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAI.0b013e318074ef99 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Knowledge and Attitudes of Patients with Rheumatoid Diseases towards Biosimilars.
Mediterr J Rheumatol
December 2024
PanHellenic Federation of Patients, Parents, Caregivers and Friends of Children with Rheumatic Diseases (RHEUMAZIN), Athens, Greece.
Objective: To assess patients' understanding and attitudes towards biosimilars in rheumatoid diseases in Greece.
Methods: A convenience sample of patients with rheumatoid diseases who were members of the largest rheumatoid patient association (RHEUMAZIN) in Greece was selected for this survey. Data on patients' knowledge and attitudes towards biosimilars were collected with a web-based questionnaire.
Safety study on switching from intravenous to fixed‑dose subcutaneous formulation of pertuzumab and trastuzumab.
Mol Clin Oncol
March 2025
Department of Pharmacy, Saitama Cancer Center, Ina, Saitama 362-0806, Japan.
To the best of our knowledge, there have been no reports from clinical settings regarding safety information on a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PHESGO) when switched from the intravenous formulation of pertuzumab and trastuzumab in Japan. The lack of information on switching from the intravenous formulation to PHESGO in clinical settings may contribute to hesitation in making the switch. The present study analyzed the safety of 51 patients with breast or colorectal cancer treated with PHESGO.
View Article and Find Full Text PDFLetermovir should be first-line cytomegalovirus prophylaxis in lung transplant recipients.
Am J Transplant
January 2025
Division of Pulmonary and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA.
Universal cytomegalovirus (CMV) prophylaxis is recommended for at-risk lung transplant recipients. Valganciclovir is currently the preferred first-line agent. Valganciclovir-related myelosuppression, however, can lead to drug discontinuation or reduction in anti-metabolite immunosuppression.
View Article and Find Full Text PDFMinimum initiatory concentration distribution of Mecillinam in clinical Staphylococcus saprophyticus isolates from Europe.
J Glob Antimicrob Resist
January 2025
Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
Background: Staphylococcus saprophyticus is the second most common bacteria causing uncomplicated urinary tract infections (UTI). It is considered non-susceptible to mecillinam, with no defined breakpoint and only few available minimal inhibitory concentration (MIC) observations. However, this consideration does not correlate with clinical outcome.
View Article and Find Full Text PDFManagement of hypertension in the early postpartum: A randomized controlled trial.
Pregnancy Hypertens
January 2025
Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Objectives: To evaluate blood pressure control during the immediate postpartum period in hypertensive women who had used methyldopa during pregnancy, comparing continuation of that drug with switching it for captopril.
Study Design: A single-blind, randomized clinical trial involving 172 postpartum women with hypertension who had previously used methyldopa during pregnancy at a minimum dose of 750 mg/day for at least one week prior to delivery. The subtypes of hypertension included were gestational hypertension, chronic hypertension, preeclampsia, superimposed preeclampsia, HELLP syndrome and eclampsia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!